Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of FOLFOX With Bevacizumab (Avastin(TM)) in Metastatic or Unresectable Gastroesophageal and Gastric Cancer

NCT00673673 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT00673673
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00673673 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of FOLFOX With Bevacizumab (Avastin(TM)) in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
Lead sponsor
Yale University
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2008
Completion date
July 31, 2014
Enrollment
39 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, gastroesophageal cancer